153 results about "Antidepressants drugs" patented technology

Disclosed is an extended or controlled release dosage form of citalopram or its related forms and other newer antidepressants for oral administration to treat chronic patients suffering from depression and to minimize the side effects associated with the current drug treatment.

This invention relates to a method for producing Hypericum perforatum hyperoside and hypericin. This invention comprehensively utilizes Hypericum perforatum fruits which are rich in our country to produce both hyperoside and hypericin pharmaceutical active components with high recovery rate, high product purity, and low cost. During the producing process, it achieves the recovery and cycling use of many solvents like ethanol and ethyl ether, and also achieves the regeneration and cycling use of micelle reextracting agent and absorption resin. The plant biological active compounds produced by this invention can be broadly used in heat-clearing and detoxifying, astringing to arrest bleeding and promote diuresis, and antidepressant drug.

A process is described for the preparation of substantially pure fluvoxamine maleate, an important antidepressant drug of the formula I, for use as an active pharmaceutical ingredient (API), from the corresponding oxime viz 5-methoxy-4'-trifluoromethylvalerophenone oxime of formula II.

The invention relates to a biological chip, in particular to a biological chip-based antidepressant drug curative effect risk evaluating system. The biological chip-based antidepressant drug curative effect risk evaluating system is characterized by consisting of a biological chip, a study optimizing module, a curative effect evaluating module, a database management module and a clinical case management module. The biological chip in the invention has the capability of continuous studying and optimizing, the application and the popularization of the biological chip in the invention provide an explicit and convenient means for forecasting the clinical treatment effect of the depression, and a far-reading social influence is generated.

The invention relates to the field of drug synthesis, and in particular relates to a preparation method of an antidepressant drug-vilazodone. The preparation method is characterized by comprising the following steps of: protecting a 1-location nitrogen atom of 5-cyano benzopyrrole used as an initial raw material through utilizing toluenesulfonyl, carrying out 3-location Friedel-Carfts acylation, and selectively reducing carbonyl into methylidyne so as to obtain 1-tosyl-3-(4-chlorobutyl)-5-cyano benzopyrrole; reacting the 1-tosyl-3-(4-chlorobutyl)-5-cyano benzopyrrole with 5-(piperazine-1-radical) benzofuran-2-nonanoic acid-ethyl ester hydrochloride, hydrolyzing through one step, and removing tosyl and ethyl at the same time so as to obtain 5-(4-(4-(5-cyan-1H-benzopyrrole-3-radical) butyl) piperazine-1-radical) benzofuran-2-carboxylic acid; finally, amidating so as to obtain vilazodone, and salifying vilazodone with hydrogen chloride so as to obtain hydrochloric acid vilazodone. The method can be used for overcoming a plurality of defects of a conventional synthetic method, and has the advantages of easiness in raw material acquisition, high yield, good selectivity, convenience in operation, suitability for industrial production and high application value.

The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine A_2A receptor antagonistic activity such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof and an antidepressant drug (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenalin reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin-noradrenalin reuptake inhibitor, a monoamine oxidase inhibitor, a 5-HT₂ antagonist or the like), and the like.

The invention discloses a process for preparing hexahydrophenol derivative for making the intermediate of venlafaxime, a novel antidepressant drug, comprising the steps of, choosing suitable dissolvent and reaction condition, by the action of initiation nitriles or polyamides compounds having general formula (3) with alkali metal chloride hydrogenated or organic lithium derivatives, compound having general formula (2) can be obtained, under suitable dissolvent and reaction conditions, compounds having general formula (2) can be transformed into compounds having general formula (1) through aluminium-hydrogen compounds reduction or catalytic hydrogenation with nickel presence. The product is antidepressant drug with proven curative effects.

The present invention relates to the novel vortioxetine salts, solvates and crystalline forms thereof, specifically, vortioxetine hemihydrobromide and a crystalline form thereof, and isopropanol solvate of vortioxetine hydrobromide and a crystalline form thereof. Compared to the known vortioxetine hydrobromide, the vortioxetine salts, solvates and crystalline forms of the present invention have improved features in stability, hygroscopicity and purity. The present invention also relates to preparation methods of the vortioxetine salts, solvates and crystalline forms, pharmaceutical compositions thereof and their uses in the manufacture of antidepressant drugs.

Provided herein methods of screening for potential antidepressant compounds effective to increase production of cellular CDP-diacylglycerol and synthesis of inositol phospholipid in depression-related areas of the brain. Also, provided are methods of diagnosing and treating depressive or mood disorders in a subject by administering these screened antidepressant compounds. Further provided is a method of determining the therapeutic efficacy of an antidepressant drug regimen by comparing the ratio of CDP-diacylglycerol/inositol phosphate after treatment to a basal ratio in a subject.

This invention belongin to medicinal chemistry, pubilize the structure and synthesis of aryl-diethylenediamine modified benzo[b]thiophenes with antidepressant function. Its structure is depicted as picuture. Ar structure is as depicted.the synthesis of the compound is as followings: mix 1M 3-propionyl benzo[b]thiophenes,1-5M cavaform and 1-5M aryl-piperazidine hydrochlorate in 1-50 weight folds ethanol, inverse flowing react 1-80 hours, obtain 1-( benzo[b]thiophenes-3)-2- methyl-3-( 4-aryl-piperazidine-)1- acetone; Mix 1M 1-( benzo[b]thiophenes-3)-2- methyl-3-( 4-aryl-piperazidine-)1- acetone and 0.2-5M sodium borohydride in 1-50 weight folds of ethanol, react at 0-100deg C for 1-20, 1-( benzo[b]thiophenes-3)-2- methyl-3-( 4-aryl-piperazidine-)1- propanol obtained. This kind of compounds could be used for antidepressant drug preparation in the form of free alkali or salt. This invention is advantageous in simplied preparation and easy manipulation.

The invention discloses application of a maidenhair total flavone extract in preparation of an antidepressant drug. A preparation method of the maidenhair total flavone extract comprises the steps that (1) through an aqueous solution, maidenhair is extracted at least one time to obtain an extracting solution, and the extracting solution is concentrated to obtain a concentrated solution; (2) 95% alcohol (alcohol/water volume ratio) is added to the concentrated solution for adjustment so as to enable the alcohol concentration to be 70% (alcohol/water volume ratio), then the concentrated solution is refrigerated at the temperature of 4 DEG C and stored for 12-24 h, centrifugation is conducted, and a supernatant is taken; (3) the supernatant is extracted through water-saturated normal butanol, a normal butanol extracting solution is merged, concentrating and drying are conducted, and then the maidenhair total flavone extract is obtained. According to the maidenhair total flavone extract, the weight content of total flavone measured according to the colorimetric method is higher than 40%. Through a pharmacological test, it is certified that the maidenhair total flavone extract has a high antidepressant effect and is high in purity, simple, convenient and practical in preparation method, suitable for industrial production and capable of serving as a crude drug separately or by combining other drugs to be applied to preparation of the antidepressant drug.

The invention provides a novel application of swertisin and a derivative thereof in preparing an antidepressant drug. The swertisin has an obvious antidepressant effect, can significantly improve functions of a monoamine neurotransmitter system, has an auxiliary therapeutic effect for depression and symptoms thereof, and provides a novel selection for treating depression clinically.

The invention relates to a duloxetine derivative and a method for preparing the same, which belongs to the chemistry field of medicine with antidepressant activity. The structural formula is as shown in the right formula, wherein R is aryl radical or tertiary butyl. The method for preparing the duloxetine derivative comprises the following steps: step one, dissolving duloxetine in dichloromethane in a reactor, adding an acid-binding agent into the mixture, stirring the mixture at room temperature for 20 minutes, and then dripping chloroacetic chloride into the mixture to react at a temperature of between 0 and 30 DEG C for 1 to 5 hours to generate an amide compound 1; and step two, dissolving the amide compound 1 generated in the step one in acetonitrile in the reactor, adding sodium iodide and triethylamine into the mixture of which the mol ratio of the amide compound 1 to the odium iodide to the triethylamine is 1 to 0.003 to (1.5 to 3), and then adding a piperazine compound into the mixture of which the mol ratio of the amide compound 1 to the piperazine compound is 1 to 1 to react at a temperature of 80 DEG C for 4 to 10 hours so as to obtain the target product. The duloxetine derivative prepared by the method has multiple mechanisms of action simultaneously, and can be used for preparing antidepressant drugs. Besides, the preparation process is simple and easy to operate.

The invention discloses an antidepressant drug and is that gardenia (parched) water or alcohol extraction is mixed with pharmaceutically suitable carrier through the mixture of macroporous resin isolation and purification part (effective part I) and cyperus tuber (vinegar bake), Chuanxiong rhizome and Chinese atractylodes (parched) ethanol extraction water-insoluble fraction (effective part II); then mixture is prepared into various preparation. The invention also discloses the preparation method and the medical application of the antidepressant drug.

The invention relates to a preparation method of an antidepressant drug Vortioxetine, which belongs to the technical field of pharmaceutical chemicals. According to the method, by taking water as a solvent, a compound 2,4-dimethylbenzenethiol shown in a formula (4), a compound 2-bromoiodobenzene shown in a formula (3) and a compound piperazine shown in a formula (2) react with copper iodide, a phase transfer reagent and alkali in an aqueous solution so as to obtain a compound shown in a formula (1). The method disclosed by the invention is easily-obtained in raw materials and simple in process; and one-pot reaction operation can be performed, and water is taken as a solvent, so that the method is green and environmental-friendly, and facilitates the industrialized production of the bulk drug.

The invention relates to a composite which is composed of (2Z, 8Z, 10E)-2,8,10-pentadecane triene-4,6-diyne-1-alcohol and (2Z, 8E, 10E)-2,8,10-pentadecane triene-4,6-diyne-1-alcohol according to the proportion of 1:(1-4) or is composed of (2Z, 8Z, 10E)-2,8,10-heptadecane triene-4,6-diyne-1-alcohol and (2Z, 8E, 10E)-2,8,10-heptadecane triene-4,6-diyne-1-alcohol according to the proportion of 1:(1-4). The composite disclosed by the invention is obtained by being extracted and separated from traditional Chinese medicine radix bupleuri. The result of an in-vitro monoamine neurotransmitter reuptake inhibition experiment shows that the composite disclosed by the invention has triple inhibition effects on the reuptake of 5-HT (5-Hydroxytryptamine), NA (noradrenalin) and DA (Dopamine), is higher than the effective part of ease powder petroleum ether and the part of radix bupleuri petroleum ether in inhibition ratio and is higher than positive control drugs, namely fluoxetine, norpramin and 6-hydroxydopamine, in inhibiting effect. According to the invention, two composites can be applied to prepare a drug used for preventing and curing depression.

The invention relates to a novel medical application of a pharmaceutical composition and in particular relates to application of a traditional Chinese medicine composition in the preparation of medicines for preventing and treating depression. The experiment proves that the traditional Chinese medicine composition is obvious in curative effect of depression, fast in effectiveness and small in toxic and side effects and is a safe antidepressant drug.

The invention discloses a method for detecting the concentration of antidepressant drugs in serum by an ultra-high performance liquid chromatography-tandem mass spectrometry technology. The antidepressant drugs comprise bupropion, agomelatine, hydroxybupropion, nortriptyline, o-desmethylvenlafaxine, mianserin, mirtazapine, venlafaxine, amitriptyline, doxepin, norfluoxetine hydrochloride, duloxetine, fluoxetine, fluvoxamine, citalopram, paroxetine, trazodone and vortioxetine. After a serum sample is pretreated, a to-be-detected substance is separated from a serum matrix by utilizing ultra-highperformance liquid chromatography, a calibration curve is established by utilizing a mass spectrum isotope internal standard quantitative method and taking a concentration ratio of the standard substance to an internal standard substance as an X axis and a peak area ratio of the standard substance to the internal standard substance as a Y axis, and the content of the drugs in serum is calculated.The method is high in sensitivity, high in specificity, accurate and simple in pretreatment process, separation and detection can be completed within 4.5 min, and the accuracy degree and precision basically meet the requirements.

The present invention provides assays, methods and compositions for selecting a treatment regimen for a patient having depression or at risk for depression and/or treating at least one symptom of depression in the subject, based on the recognition that specific combinations of single nucleotide polymorphisms (SNPs) are associated with a therapeutic response to a folate-comprising compound. Provided herein are also methods for improving the effectiveness of an antidepressant drug administered to a subject with depression or at risk for depression by administering an adjunctive therapy of a folate-comprising compound to the subject if the subject carries a specific combination of SNPs that are predictive of a therapeutic response. Furthermore, provided herein are compositions of the folate-comprising compound.

The invention aims to provide application of a fine-leaf schizonepeta herb extract in preparation of antidepressant drugs. The fine-leaf schizonepeta herb extract is a fine-leaf schizonepeta herb water extract or a fine-leaf schizonepeta herb alcohol extract, wherein the fine-leaf schizonepeta herb water extract is a dried substance obtained by smashing a fine-leaf schizonepeta herb into traditional Chinese medicine powder, adding water for soaking, boiling the powder twice, mixing two medicinal liquids and performing concentration and drying, and the fine-leaf schizonepeta herb alcohol extract is a dried substance obtained by smashing the fine-leaf schizonepeta herb into traditional Chinese medicine powder, adding ethyl alcohol for soaking, reflux extraction is performed twice, mixing two extracting liquids and performing concentration and drying. The raw materials are rich, a preparation method is simple, the prepared fine-leaf schizonepeta herb extract has an antidepressant effect and is effectively used for preparing the antidepressant drugs, application of the fine-leaf schizonepeta herb extract in drug preparation is achieved, the application value of the fine-leaf schizonepeta herb is increased, and the fine-leaf schizonepeta herb extract is the innovation in traditional Chinese medicine and has good economic and social benefits.

The invention provides a pepper extract and a preparation method and application thereof. The pepper extract is extracted and refined from different parts of pepper, has antidepressant activity and particularly has an obvious inhibitory effect on depression associated with monoamine oxidase A (MAO-A). The invention also provides the application of the pepper extract in preparing antidepressant drugs.

The invention discloses use of lentinan as an antidepressant drug, belongs to the field of medicine, and is characterized in that the lentinan or a lentinan derivative is used as an active component to prepare the antidepressant drug; the lentinan derivative is a glycoside prepared from the lentinan and a pharmaceutically acceptable salt, ester or sugar thereof; the antidepressant drug is used for the treatment or prevention of depression, has the advantages of significant anti-depression effect, quick effect, less side effect and the like, and is therefore an excellent anti-depression drug candidate.